RenovoRx Reports 115% Revenue Growth in Q2 2026 Amid Ongoing Losses

RenovoRx, Inc. reported its financial results for the second quarter of 2026, revealing a significant increase in revenue and ongoing operational challenges. The company generated $909,000 in revenue for the three months ended June 30, 2026, marking a 115% increase compared to $422,000 in the same period last year. For the first half of 2026, total revenue reached $1.472 million, up from $619,000 in the first half of 2025. Despite this growth, RenovoRx continues to face substantial losses, reporting a net loss of $2.911 million for the second quarter and $6.432 million for the first half of the year, compared to losses of $2.895 million and $5.315 million, respectively, in the prior year.

The company's operational metrics indicate a strategic shift towards commercialization, with the number of active commercial cancer centers increasing from 16 to 21 in less than a quarter. RenovoRx is actively expanding its customer base, with 42 additional centers in various stages of evaluation and approval. The company aims to reach 36 active centers by the end of 2026. This expansion is supported by a growing interest in the RenovoCath device, which is designed for targeted drug delivery in oncology treatments. The company has also begun supporting investigator-initiated trials for additional cancer types, further broadening its market potential.

RenovoRx's operating expenses increased significantly, with total operating expenses for the second quarter rising to $4.115 million from $2.948 million in the same period last year. This increase was primarily driven by higher selling, general, and administrative costs, which rose to $2.915 million, reflecting investments in expanding the commercialization of RenovoCath. Research and development expenses decreased slightly to $1.2 million, down from $1.426 million, as the company continues to manage costs associated with its ongoing clinical trials.

The company’s balance sheet as of June 30, 2026, showed total assets of $11.472 million, up from $8.095 million at the end of 2025, primarily due to increased cash and cash equivalents, which rose to $9.479 million. RenovoRx has raised approximately $81.4 million since its inception, with the latest funding round in March 2026 generating $10 million. However, the company acknowledges the need for additional capital to support its ongoing operations and commercialization efforts, as it does not expect to achieve positive cash flows in the near future.

Looking ahead, RenovoRx remains focused on its commercialization strategy for RenovoCath and the ongoing Phase III TIGeR-PaC clinical trial for its lead product candidate, intra-arterial gemcitabine (IAG). The company anticipates that the completion of the trial will provide valuable data to support its product offerings. Despite the challenges, RenovoRx is optimistic about its growth trajectory, driven by increased customer engagement and the potential for expanded applications of its technology in oncology.